SS-31 (Elamipretide)

What Is SS-31?

SS-31, also known as elamipretide, is a synthetic mitochondria-targeting tetrapeptide developed to selectively localize to the inner mitochondrial membrane. It belongs to a class of aromatic–cationic peptides engineered to penetrate cell membranes and accumulate within mitochondria independent of membrane potential.

Its defining biological characteristic is its ability to bind cardiolipin, a specialized phospholipid unique to the inner mitochondrial membrane. Cardiolipin plays a critical structural and functional role in stabilizing the electron transport chain and maintaining mitochondrial cristae architecture.

A detailed scientific review outlining SS-31’s structure, cardiolipin interaction, and mitochondrial relevance can be found here:

https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/

Layman’s Explanation (Plain Language)

Mitochondria are often referred to as the “energy factories” inside nearly every cell. They generate ATP, the molecule that powers cellular function. When mitochondria become dysfunctional — whether due to genetic variation, cellular stress, or age-related changes — energy production may decline and oxidative stress may increase.

SS-31 is studied because it appears to attach to one of the key structural lipids (cardiolipin) inside mitochondria. Researchers investigate whether stabilizing this structure may help mitochondria maintain more efficient energy production and better manage oxidative stress.

A mechanistic overview describing how SS-31 accumulates in mitochondria and interacts with cardiolipin is detailed here:

https://pmc.ncbi.nlm.nih.gov/articles/PMC7935714/

Mechanism of Action (Mitochondrial Targeting and Cardiolipin Binding)

The primary research interest surrounding SS-31 centers on its:

• Direct binding to cardiolipin within the inner mitochondrial membrane
• Stabilization of mitochondrial cristae architecture
• Reduction of pathological reactive oxygen species (ROS)
• Support of oxidative phosphorylation efficiency

A comprehensive mitochondrial protein interaction study published in Proceedings of the National Academy of Sciences (PNAS) mapped SS-31’s interaction landscape and demonstrated its association with multiple mitochondrial proteins involved in respiration and membrane structure:

https://www.pnas.org/doi/10.1073/pnas.2002250117
This work provides molecular-level support for its bioenergetic research applications and expands understanding beyond simple cardiolipin interaction.

Human Clinical Research

Barth Syndrome

A randomized, double-blind, placebo-controlled crossover trial evaluated elamipretide in genetically confirmed Barth syndrome patients. The study assessed muscle strength, cardiac parameters, and functional capacity over time.

Full publication:

https://pmc.ncbi.nlm.nih.gov/articles/PMC7935714/

This research contributes to the translational understanding of mitochondrial membrane stabilization in rare mitochondrial disorders.

Primary Mitochondrial Myopathy (MMPOWER-3)

The Phase 3 MMPOWER-3 study evaluated elamipretide in patients with primary mitochondrial myopathy. The trial did not meet its primary endpoints, including six-minute walk distance and fatigue measurements. These results underscore the importance of indication-specific investigation when studying mitochondrial-targeted compounds.

Publication detailing trial results:

https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/

This study remains important in defining both the potential and limitations of mitochondrial bioenergetic interventions.

Ophthalmology Research (Retinal Disease)

Elamipretide has been investigated in ophthalmic research programs exploring mitochondrial stabilization in retinal tissue, which is highly energy-dependent.

Dry Age-Related Macular Degeneration (Phase 1 study):

https://pmc.ncbi.nlm.nih.gov/articles/PMC9560640/

ReCLAIM-2 Phase 2 Study (visual acuity endpoints):

https://www.ophthalmologyscience.org/article/S2666-9145(24)00164-7/fulltext

Leber Hereditary Optic Neuropathy (LHON) topical study:

https://www.aaojournal.org/article/S0161-6420(23)00802-3/fulltext

These investigations explore mitochondrial membrane support in high-metabolic-demand tissues.

Preclinical and Translational Research

In preclinical models, SS-31 has demonstrated:

• Improvements in mitochondrial respiration
• Reduction in oxidative stress markers
• Preservation of mitochondrial membrane structure

An aging-related visual impairment mouse model publication:

https://pmc.ncbi.nlm.nih.gov/articles/PMC8891924/

These findings provide foundational mechanistic data for laboratory research involving mitochondrial bioenergetics and membrane stabilization.

Areas of Active Scientific Interest

Researchers studying SS-31 frequently focus on:

• Cardiolipin oxidation and inner membrane integrity
• Cristae ultrastructure and electron transport chain organization
• Mitochondrial respiration efficiency
• Oxidative stress modulation
• Tissue-specific mitochondrial energetics

A biochemical review summarizing SS-31’s mitochondrial targeting properties and translational relevance is available here:

https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/

Safety and Tolerability (Published Context)

Across published clinical programs, elamipretide has been described as generally tolerated in studied populations, though efficacy has varied by condition and endpoint. Researchers are encouraged to consult primary literature directly when evaluating safety profiles in specific trial settings.

Comprehensive prescribing and safety documentation can be reviewed via:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf

Compliance Statement

SS-31 (elamipretide) is intended for research use only.

Not for human consumption.

Information provided is for scientific and educational purposes and does not constitute medical advice or therapeutic claims.